| Name | Title | Contact Details |
|---|
Centric Medical Communications, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VHA Inc. is a national network of not-for-profit health care organizations working together to improve performance and efficiency in clinical, financial and operational management. Since 1977, when VHA established the first hospital membership organization, the company has applied its knowledge in analytics, contracting, consulting and network development to help members and customers achieve their strategic objectives. In 2012, VHA delivered $1.9 billion in savings and additional value to members. Serving 5,100 health system members and affiliates, VHA represents more than a quarter of the nation's hospitals. VHA also serves more than 118,000 non-acute health care customers enterprise-wide. VHA is based in Irving, Texas, and has 12 regional offices across the U.S. VHA, together with UHC, owns Novation, a supply chain company, and aptitude™ , the health care industry's first online direct contracting market. VHA also owns Provista, a supply chain company serving the non-acute market as well as hospitality, education and corporate markets.
Saint Luke's Hospital of Kansas City is a 582-bed tertiary care hospital offering many specialized programs and services, with a network of 550 physicians practicing in more than 56 medical specialties.
Gritman Medical Center, Inc. operates hospitals and healthcare facilities. The company was founded in 1893 and is based in Moscow, Idaho.
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope`s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.